Afatinib in Advanced Refractory Urothelial Cancer

Overview

This phase II trial studies how well afatinib dimaleate works in treating patients with urothelial cancer that cannot be removed surgically and has grown after treatment with standard first-line chemotherapy. Afatinib dimaleate may turn off the function of the epidermal growth factor (EGF) and human epidermal growth factor receptor 2 (HER2) receptors, which may slow the growth of cancer cells or cause some of the cells to die.

Full Title of Study: “Afatinib Dimaleate in Treating Patients With Advanced Refractory Urothelial Cancer”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 12, 2022

Detailed Description

PRIMARY OBJECTIVES: I. To determine the 3-month progression free survival (PFS) rate in metastatic urothelial cancer patients receiving afatinib (afatinib dimaleate) who have progressed despite prior platinum-based chemotherapy. SECONDARY OBJECTIVES: I. To determine the overall response rate (complete response [CR] + partial response [PR]), median progression free survival, and overall survival for the same treated population. II. To determine whether tumor epidermal growth factor receptor (EGFR) and/or HER2 overexpression influences 3-month PFS in patients treated with afatinib. OUTLINE: Patients receive afatinib dimaleate orally (PO) once daily (QD) on days 1-42. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months.

Interventions

  • Drug: afatinib dimaleate
    • Given PO
  • Other: laboratory biomarker analysis
    • Correlative studies

Arms, Groups and Cohorts

  • Experimental: Treatment (afatinib)
    • Patients receive afatinib dimaleate PO QD on days 1-42. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.

Clinical Trial Outcome Measures

Primary Measures

  • Progression-free survival (PFS)
    • Time Frame: 3 months
    • Estimated using the Kaplan-Meier method.

Secondary Measures

  • Overall response rate (CR + PR)
    • Time Frame: Up to 3 years
  • Median progression-free survival (PFS ) time
    • Time Frame: Up to 3 years
    • Estimated using the Kaplan-Meier method.
  • Overall survival
    • Time Frame: Up to 3 years
    • Estimated using the Kaplan-Meier method.
  • EGFR expression status
    • Time Frame: Baseline
    • Relationship to 3-month PFS will be determined.
  • HER2 expression status
    • Time Frame: Baseline
    • Relationship to 3-month PFS will be determined.

Participating in This Clinical Trial

Inclusion Criteria

  • Patients must have locally advanced or metastatic urothelial cancer that is not amenable to surgical treatment – Patients must have histologically or cytologically confirmed urothelial tract carcinoma; patients with urothelial carcinoma of the bladder, upper tract, or urethra are eligible – Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 20 mm with conventional techniques or as >= 10 mm with spiral computed tomography (CT) scan for the evaluation of measurable disease (Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v1.1]) – Patients must have evidence of disease progression prior to enrollment – All patients must have received a prior platinum-based chemotherapy regimen for treatment of urothelial cancer and must now be considered refractory to platinum-based chemotherapy; patients may have received the platinum-containing regimen either in the peri-operative or metastatic setting – Patients may have received up to one line of prior systemic chemotherapy for recurrent/metastatic disease; if a platinum-based regimen was received both in the peri-operative setting and again in the metastatic setting, this will be considered 1 line of chemotherapy – Eastern Cooperative Oncology Group (ECOG) performance status 0-1 – Absolute neutrophil count >= 1,000/mcL – Platelets >= 100,000/mcL – Hemoglobin >= 8.5g/dL – Total bilirubin =< 1.5 institutional upper limit of normal (IULN) – Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X IULN – Calculated creatinine clearance >= 30 mL/min by the modified Cockcroft and Gault Formula OR glomerular filtration rate >= 30 mL/min/body surface area (BSA) by Modification of Diet in Renal Disease or Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula – Women and men of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately – Patients must have the ability to understand and the willingness to sign a written informed consent document Exclusion Criteria:

  • Patients may not be receiving any other investigational agents – Patients with untreated known brain metastases, or treated brain metastases that are clinically unstable – Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements – Women known to be pregnant – Women who are breastfeeding and who are unwilling to stop breastfeeding prior to study entry – Patients with known prior human immunodeficiency virus (HIV)-positive status on combination antiretroviral therapy are ineligible; known prior HIV-positive patients with CD4+ =< 500/mm^3 are ineligible (HIV testing is not required as part of this study) – Pre-existing interstitial lung disease – Inability to take oral medications – Prior therapy with afatinib

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Chicago
  • Collaborator
    • National Cancer Institute (NCI)
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Peter O’Donnell, Principal Investigator, University of Chicago

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.